Clinical Trial Update: Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) [Phase 3]

View source ↗

Summary

Phase 3 study comparing WR 279,396 to paromomycin alone for cutaneous leishmaniasis completed; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Paromomycin (paromomycin)
• WR 279,396

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Cutaneous Leishmaniasis | Phase 3 | Status: COMPLETED | Results posted: 2014-07-14